The whiplash over a new potential flu vaccine from Moderna, which went from rejected to approved for review in a matter of days, has illustrated a new reality plaguing the Cambridge biotech company ...
For community members, a listening session about the recently axed Parcel 3 development project was a chance to question the ...
Chinese pharmaceutical companies that as a group chalked up record outbound licensing agreements with international industry ...
As the CGT market evolves, developers must answer one key question that will shape their manufacturing strategy: “Should we go with a modular platform or a fully integrated system?” Both approaches ...
The FDA’s refusal to review Moderna’s mRNA-based flu vaccine is “part of a disturbing pattern” of moving regulatory goalposts, according to Clay Alspach, executive director of the Alliance for mRNA ...
WATERFORD, CT, UNITED STATES, February 3, 2026 /EINPresswire.com/ -- Empowering Financial Confidence Through Strategic ...
Delivering Integrated Reaction, Crystallization, Filtration, and Drying Solutions for Advanced Semiconductor Materials ...
ORLANDO, FL, UNITED STATES, January 27, 2026 /EINPresswire.com/ -- Orakle LLC is pleased to announce the launch of a ...
No deathswere recorded in relation to alleged administration of expired COVID-19 Pfizer vaccines on patients,Assistant ...
FLORENCE, CA, UNITED STATES, February 9, 2026 /EINPresswire.com/ -- Helping Professionals Land Interviews and Offers ...
LIGAND-AI is a flagship project of the Target 2035 initiative, funded by the Innovative Health Initiative, a public-private partnership (PPP) between the European Union and the European life science ...
The Food and Drug Administration rejected Moderna's new flu shot. This raises questions about what it means for the future of vaccine development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results